Stable Supply and Minimisation of Business Risks Amid the Impact of COVID-19
First written in FY2020-Q2. 8 of 11 entries say "Restated". Latest entry: FY2023-Q1.
The whole theme swung hardest in 2026: 1 of 12 companies on the "Worse" side.
108 other companies' latest entry also says "Restated".
- FY2023-Q1RestatedAnnual report
「Under these circumstances, the Group continued to implement COVID-19 infection-control measures and, with a view to contributing to a sustainable society, pursued product development addressing market requirements and research and development using its proprietary optical technologies, striving to secure revenue and profit.」
The Group has reaffirmed its efforts to continue infection-control measures while pursuing product development addressing market requirements and research and development using its proprietary optical technologies. - FY2022RestatedAnnual report
「The Group continued to implement infection-control measures to prevent the spread of COVID-19 among employees and its impact on production activities, while continuing capital investment to expand production capacity. With a view to contributing to a sustainable society, it also pursued research and product development using its proprietary optical technologies, striving to increase revenue and profit.」
The Group continues to operate its business by combining infection control, the maintenance and expansion of production activities, capital investment, and research and product development. - FY2022-Q3RestatedAnnual report
「While continuing to operate after implementing measures to prevent COVID-19 infections and seeking to minimize business risks, the Group worked to secure revenue and profit by maintaining production to meet market requirements. At the same time, with a post-COVID-19 environment in mind, it continued active capital investment for the future and promoted research and development that leverages our proprietary optical technologies.」
We continue to implement infection-prevention measures, minimize business risks, maintain production activities, make proactive capital investments, and conduct research and development using our proprietary optical technologies. - FY2022-Q2RestatedAnnual report
「While continuing to implement measures to prevent COVID-19 infections and keeping in mind our contribution to a sustainable society, the Group has worked to secure sales and profits by promoting research and development using our proprietary optical technologies cultivated over many years.」
The policy of continuing infection-prevention measures while pursuing research and development using our proprietary optical technologies to secure sales and profits has been reconfirmed. - FY2022-Q1RestatedAnnual report
「While continuing to implement measures to prevent COVID-19 infections and keeping in mind our contribution to a sustainable society, we have worked to secure sales and profits by pursuing research and development and product development using our proprietary optical technologies.」
The policy of continuing COVID-19 infection-prevention measures while pursuing research and product development using our proprietary optical technologies to secure sales and profits has been reconfirmed. - FY2021-Q3RestatedAnnual report
「While continuing to operate after implementing measures to prevent COVID-19 infections and seeking to minimize business risks, the Group worked to secure revenue and profit by maintaining production to meet market requirements. At the same time, with a post-COVID-19 environment in mind, it continued active capital investment for the future and promoted research and development that leverages our proprietary optical technologies.」
We continue to implement infection-prevention measures, minimize business risks, maintain production activities, make capital investments, and conduct research and development using our proprietary optical technologies. - FY2021-Q2RestatedAnnual report
「While continuing to operate after implementing measures to prevent COVID-19 infections, the Group worked to secure revenue and profit by pursuing product development that responds to market requirements and research and development that leverages our proprietary optical technologies.」
We continue to implement infection-prevention measures, maintain business continuity, develop products in response to market needs, and conduct research and development using our proprietary optical technologies. - FY2021-Q1RestatedAnnual report
「In this environment, the Group worked to minimize business risks, including by promoting the stable supply of products after implementing measures to prevent COVID-19 infections, and to secure revenue and profit by promoting product development that responds to market requirements and research and development that leverages our proprietary optical technologies.」
We continue to implement infection-prevention measures, ensure a stable product supply, minimize business risks, develop products in response to market needs, and conduct research and development using our proprietary optical technologies. - FY2020AdvancedAnnual report
「To prevent employee infections and the spread of infection, ensure safety and minimize the impact on our production activities, we prohibited domestic and overseas business travel, prohibited participation in meetings involving large numbers of unspecified participants, such as seminars, exhibitions and social gatherings, and asked customers to refrain from visiting our offices.」
Measures to ensure business continuity and liquidity amid the impact of COVID-19 are specified, including restrictions on business travel, meetings and visits, infection-prevention measures, a review of investment plans and the establishment of a commitment line. - FY2020-Q3AdvancedAnnual report
「In these circumstances, the Group worked to prevent employee infections, the spread of infection and disruption to production activities, and sought to minimize business risks by ensuring a stable supply of products after implementing infection-prevention measures. As a result, although there was no major impact on product manufacturing or the procurement of components, sales were significantly affected by COVID-19.」
The results of implementing infection-prevention measures and working to ensure a stable product supply and limit the impact on manufacturing and component procurement are described. Meanwhile, sales were significantly affected. - FY2020-Q2First statedAnnual report
「While taking into account the impact of COVID-19 on the global economy, we will work to minimize business risks, including by ensuring a stable supply of our products, and strengthen our sales structure and make capital investments in preparation for future sales growth.」
In light of the impact of COVID-19, new measures to ensure a stable product supply, minimize business risks, strengthen the sales structure and make capital investments have been described.